Abstract
Natural antibodies are preformed antibodies that are present even in naive germ-free mice in the absence of any exogenous antigenic exposure. Consistent with their specificities for microbial antigens, natural antibodies play an important non-redundant role in the first line defense against bacterial and viral infections. On the other hand natural antibodies have also been shown to have specificities for self antigens, and therefore have been proposed to provide important homeostatic “house-keeping” functions. Many of the recognized self-antigens may in fact be stress-induced self-antigens, such as oxidation-specific epitopes that accumulate during atherogenesis as well as in many other inflammatory settings, and natural antibodies could protect from the impact of the pathological accumulation of these self-antigens. In this review we will discuss the specific example of the prototypic natural antibody T15/EO6, which is increased in atherosclerotic mice and mediates atheroprotection, and discuss the potential role of natural antibodies in atherogenesis in general.
Current Drug Targets
Title: Natural Antibodies in Murine Atherosclerosis
Volume: 9 Issue: 3
Author(s): Joseph L. Witztum, Christoph J. Binder, Meng-Yun Chou, Linda Fogelstrand, Karsten Hartvigsen, Peter X. Shaw and Agnes Boullier
Affiliation:
Abstract: Natural antibodies are preformed antibodies that are present even in naive germ-free mice in the absence of any exogenous antigenic exposure. Consistent with their specificities for microbial antigens, natural antibodies play an important non-redundant role in the first line defense against bacterial and viral infections. On the other hand natural antibodies have also been shown to have specificities for self antigens, and therefore have been proposed to provide important homeostatic “house-keeping” functions. Many of the recognized self-antigens may in fact be stress-induced self-antigens, such as oxidation-specific epitopes that accumulate during atherogenesis as well as in many other inflammatory settings, and natural antibodies could protect from the impact of the pathological accumulation of these self-antigens. In this review we will discuss the specific example of the prototypic natural antibody T15/EO6, which is increased in atherosclerotic mice and mediates atheroprotection, and discuss the potential role of natural antibodies in atherogenesis in general.
Export Options
About this article
Cite this article as:
Witztum L. Joseph, Binder J. Christoph, Chou Meng-Yun, Fogelstrand Linda, Hartvigsen Karsten, Shaw X. Peter and Boullier Agnes, Natural Antibodies in Murine Atherosclerosis, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755520
DOI https://dx.doi.org/10.2174/138945008783755520 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of X-ray, NMR, and Molecular Modeling in the Design of MMP Inhibitors
Current Topics in Medicinal Chemistry Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Phytochemistry and Phytotherapeutic Aspects of <i>Elaeagnus angustifolia L.</i>
Current Drug Discovery Technologies Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Current Pharmaceutical Design Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Activation of Central Pain Pathways in Rheumatic Diseases: What We have Learned from Functional Neuroimaging Studies
Current Rheumatology Reviews The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity
Current Rheumatology Reviews The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Comparison of Pleural Fluid TNF-α and IL-10 Levels with ADA in Tuberculous Pleural Effusion
Current Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Chronic Streptococcal and Non-Streptococcal Pharyngitis
Infectious Disorders - Drug Targets Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews IL-23/Th17 Axis: A Potential Therapeutic Target of Psoriasis
Current Drug Research Reviews COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Viscosupplementation with Intra-Articular Hyaluronic Acid for Treatment of Osteoarthritis in the Elderly
Current Pharmaceutical Design